Myogen darusentan to enter Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Myogen plans to move its selective endothelin receptor antagonist darusentan into Phase III for resistant hypertension following significant Phase II results, the firm says Aug. 18. In a 115-patient placebo-controlled trial, darusentan showed significant reductions of 11.6 mmHg (p=0.02) in systolic blood pressure and 7.0 mmHg (p<0.001) in diastolic blood pressure. Myogen is highlighing darusentan's mechanism of action as "different than those of currently approved antihypertensive drugs." Myogen shares rose more than 60% upon announcement of the results...
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.